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Withdrawal From Treatment as an
Outcome in the ISOLDE Study of COPD*
Peter M. A. Calverley, MD; Sally Spencer, BSc; Lisa Willits, PhD, MSc;
P. Sherwood Burge, MD; and Paul W. Jones, MD; on behalf of the
ISOLDE Study Group
Objectives: To investigate the determinants of patient withdrawal from our study, and the effect
of these withdrawals on the outcome of treatment with inhaled corticosteroids in patients with
COPD.
Design: A double-blind, placebo-controlled, randomized trial.
Setting: Eighteen outpatient centers in the United Kingdom.
Participants: Seven hundred fifty-one patients with stable COPD defined clinically and as
baseline postbronchodilator FEV1 > 0.8 L and < 85% predicted, FEV1/FVC ratio < 70%, and
FEV1 change after albuterol < 10% of predicted.
Intervention: Random assignment of either 500 g bid of inhaled fluticasone propionate (FP)
using a spacer device or an identical placebo inhaler. Treatment was continued for 3 years or
until patients withdrew from follow-up.
Measurements and results: Postbronchodilator FEV1 was measured on three occasions before
randomization and every 3 months thereafter. Health status was assessed by the disease-specific
St. George Respiratory Questionnaire (SGRQ) and the modified short-form 36 questionnaire
(SF-36) at baseline and every 6 months. Three hundred thirty-nine patients withdrew, of whom
156 patients received FP. Prescription of frequent courses of oral prednisolone was the most
common reason for withdrawing as specified in the protocol (69 patients in the FP group
withdrew due to respiratory symptoms, compared with 93 patients in the placebo group). This
explained the significantly greater dropout of placebo-treated patients that was most evident
when FEV1 was < 50% predicted. Patients withdrawing had a significantly more rapid decline in
health status, measured by both the SGRQ and the SF-36 (p < 0.001). Those withdrawing from
the placebo group had a more rapid decline in FEV1 and more exacerbations than the FP-treated
groups. Baseline FEV1 was lower in dropouts than in patients completing the study receiving
placebo, but there was no difference between the respective groups receiving FP.
Conclusions: Patients who withdrew from follow-up were those with the most rapidly deteriorat-
ing health status and lung function. Losing these patients from the final analysis can reduce the
power of a study to achieve its primary end point. (CHEST 2003; 124:1350–1356)
Key words: COPD; exacerbation; fluticasone propionate; patient withdrawal
Abbreviations: FP  fluticasone propionate; ISOLDE Inhaled Steroids in Obstructive Lung Disease;
SF-36 modified short-form 36 questionnaire; SGRQ St. George Respiratory Questionnaire
I n most areas of pulmonary medicine, treatment isbased on the results of carefully conducted, ran-
domized controlled trials. In diseases such as bron-
chial asthma, brief periods of follow-up are sufficient
to evaluate the effect of most drugs, including those
that modify the natural history of the disease.1,2
Treatment trials commonly last from 3 to 12 months;
in addition to conventional outcomes such as changes
in pulmonary function, symptoms, or health status, the
number of patients who withdraw from follow-up and
*From University Hospital Aintree (Dr. Calverley), Liverpool; St.
George’s Hospital Medical School (Ms. Spencer and Dr. Jones),
London; Heartlands Hospital NHS Trust (Dr. Burge), Birming-
ham; and GlaxoSmithKline (Dr. Willits), Stockley Park, UK.
Drs. Calverley, Burge, and Jones, and Ms. Spencer were all
independent investigators in the ISOLDE study from which this
work is derived. This study was supported by a grant from
GlaxoSmithKline. Ms. Willits is a statistician working for Glaxo-
SmithKline. The investigators had unrestricted access to the data
and determined its analysis throughout the study.
Manuscript received September 17, 2002; revision accepted April
14, 2003.
Reproduction of this article is prohibited without written permis-
sion from the American College of Chest Physicians (e-mail:
permissions@chestnet.org).
Correspondence to: Peter M. A. Calverley, MD, Department of
Medicine, The University Hospital Aintree, Clinical Sciences
Centre, Longmoor Lane, Liverpool L9 7AL, United Kingdom;
e-mail: pmacal@liverpool.ac.uk
1350 Clinical Investigations
their reasons for doing so are reported.3,4 This patient
dropout information provides further useful infor-
mation about the effectiveness and acceptability of
treatment.
Evaluating therapy in patients with COPD usually
takes longer, although drugs such as long-acting
inhaled -agonists can modify health status within 16
weeks.5 Changes in disease progression and, partic-
ularly in the rate of decline of FEV1, are harder to
assess, and should be monitored over at least 3 years.
There is general agreement that it is difficult to do
this in  3 years, the minimum period chosen in a
series of intervention studies6–9 using inhaled corti-
costeroids. Maintaining follow-up over 3 years poses
significant problems, as COPD is characterized by
exacerbations of disease that can lead to study
withdrawal from the study. Patient withdrawal due to
exacerbations is a particular problem when studying
inhaled corticosteroids, as courses of oral corticoste-
roids are the most effective way of speeding the
resolution of exacerbations10,11; however, if these
courses are administered frequently, the outcome of
the trial may be affected.
Patient withdrawal is not a problem when patients
are studied early in the natural history of the disease
when exacerbations are infrequent.6,7 The Inhaled
Steroids in Obstructive Lung Disease (ISOLDE)
study recruited patients with established disease. To
show a treatment effect, it was important to retain
the patients within the trial for as long as possible.
The intention-to-treat analysis of this study has now
been reported.8 In this article, we examine the
characteristics of those patients who withdrew from
the trial, and the effect the withdrawals had on our
study population and how we analyzed the data. We
believe that these data are relevant to future inves-
tigators who study patients of a similar severity, in
which patient behavior during long-term follow-up
can be very different from patients with milder
disease.
Materials and Methods
Patients
Details of the trial design and patient recruitment have been
presented previously.8 All patients had a clinical diagnosis of
nonasthmatic COPD, met the established diagnostic criteria for
this disorder,12,13 were aged 40 to 75 years inclusive, and had a
history of current or previous smoking. At baseline, postbron-
chodilator (400 g albuterol) FEV1 was  0.8 L and  85%
predicted, (FEV1/FVC) ratio was  70%, and the FEV1 change
after albuterol was  10% of predicted. Patients with a clinical
diagnosis of asthma, those requiring any nontrial anti-inflamma-
tory treatment for lung disease or -adrenergic blockers, patients
with a life expectancy  5 years due to concomitant disease, and
those unable to meet the required standards for spirometry at the
pretrial visit were excluded. Nasal and ocular topical corticoste-
roids were allowed, as were methylxanthines and long-acting
inhaled bronchodilators. All patients received albuterol, 200 g,
and ipratropium bromide, 80 g, as required throughout the
trial. The protocol was approved by the ethical review committee
of each participating center, and all subjects gave written in-
formed consent.
Spirometric Measurements (FEV1 and FVC)
Measurements were made at the same time of day for each
subject. Short-acting bronchodilators were withheld for 4 h, oral
or long-acting bronchodilators for 12 h, caffeine-containing prod-
ucts for 4 h, smoking for 2 h, and large meals for 1 h prior to
spirometric measurements. Measurements were made with pa-
tients in the seated position after 15 min of resting. Spirometry
was performed before bronchodilation, and then 30 min after
treatment with 80 g of ipratropium bromide and 400 g of
albuterol.
Health Status Measurement
The St. George Respiratory Questionnaire (SGRQ) is a super-
vised self-administered measure, designed specifically for use in
airways disease.14 It is a 50-item survey from which a total of
three component scores are calculated: symptoms (distress
caused by specific respiratory symptoms), activity (physical activ-
ities that cause or are limited by breathlessness), and impacts
(social and psychological effects of the disease). The SGRQ is
scored from 0 to 100, where 0 indicates best health and 100
indicates worst health. A change in score of 4 U is consistent with
a clinically significant change in the patient15,16; therefore, an
increase in score indicates worsening health status. The SGRQ
has been shown to be a valid measure of health impairment in
patients with chronic airflow limitation, and to respond to change
with therapy.5,14,17
General health status was assessed using the SF-36, a core
generic measure.18 It is a self-completed questionnaire contain-
ing 36 questions covering eight health concepts: physical func-
tion, physical role limitation, mental role limitation, social func-
tion, mental health, pain, energy/vitality, and health perception.
Two summary components (physical and mental) can also be
calculated by differentially weighting the scales. The SF-36 scales
are scored as a percentage of impairment, with 0 representing
worst health and 100 indicating best health. With this scale, a
decrease in score indicates worsening general health. Its reliabil-
ity is extensively documented.19
Other Baseline Measurements
Smoking history was validated with exhaled breath carbon
monoxide and urinary cotinine measurements. Smokers were
defined as those currently smoking or with a urinary cotinine
level  40 ng/mL. Ex-smokers were those who had given up
smoking, and had a urinary cotinine level  40 ng/mL Gas
transfer was measured using the single-breath method. Skin-
prick tests with diluent control, 10% histamine, and allergen
extracts of Dermatophagoides pteronyssinus, cat dander, mixed
grass pollens, and Aspergillus fumigatus were read at 15 min.
Maximum wheal diameters were measured, and atopy was
defined as a  3 mm-wheal to at least one allergen extract with
appropriate controls.
Protocol
After completing an 8-week run in period to establish clinical
stability and confirm the postbronchodilator spirometry values on
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three occasions, patients were offered a 2-week trial of oral
corticosteroids (0.6 mg/kg/d) prior to commencing 3 years of trial
medication. Treatment was randomized between 500 g of
fluticasone propionate (FP) or an identical placebo bid from a
metered-dose inhaler using a Volumatic spacer device (Allen and
Hanbury; Greenford, Middlesex, UK). The patients re-attended
were followed at 3-month intervals when postbronchodilator
spirometry was recorded, and every 3 months thereafter together
with a detailed account of all new symptoms and disease exacer-
bations. These exacerbations were defined as worsening of
respiratory symptoms that required treatment with oral cortico-
steroids or antibiotics and/or oral corticosteroids. Health status
was recorded at baseline and every 6 months thereafter.
Criteria for Withdrawal
Patients were permitted to withdraw at any time during the
study at will or at the discretion of their physician. Reasons for
withdrawal were categorized into those that were respiratory and
related to the underlying COPD and into other medical and
social reasons leading to the discontinuation of follow-up. Pa-
tients who were treated by their family physician with a course of
oral corticosteroids on three occasions during any 3-month period
were withdrawn as per protocol, automatically considered as a
study dropouts, and offered open-label therapy with inhaled
corticosteroids. Further follow-up of these patients was not
undertaken.
Data Analysis
Patients in whom 3 years of follow-up data were available from
the time of randomization were considered to be completers; all
other randomized patients were classified as noncompleters.
Student t tests were used to analyze differences in mean values
between treatment groups. A Kaplan-Meier plot was used to
compare the time to withdrawal between treatment groups. The
Fisher exact test compared treatment withdrawals by baseline
FEV1. A random coefficients hierarchical model, described
elsewhere,8 was used to determine the rates of change in FEV1
and health status for patients who completed the study and those
who withdrew. Data are expressed as mean (SD) unless stated
otherwise stated. Baseline FEV1 is the mean of data measured at
4 weeks and 8 weeks of the run-in period. Tests were two sided,
with a 15% level of significance to take into account multiple
comparisons.
Results
Demographic and Baseline Characteristics
The demographic and baseline characteristics of
the patients categorized into those completing and
withdrawing and by treatment allocation are pre-
sented in Table 1. At the beginning of the study,
there were no significant differences in gender,
atopy, smoking status, or pack-years of tobacco ex-
posure between any of these groups; however, pa-
tients who withdrew while receiving placebo were
significantly more likely to have been receiving
inhaled corticosteroids before entry into the trial.
The baseline FEV1 data did not differ between
patients who did and did not withdraw in the FP
group, but was lower in those withdrawing from
placebo. This was different at the 5% significance
level, but did not meet our post hoc criterion for
statistical significance.
Reasons for and Time to Withdrawal
Of the 751 patients randomized, 402 patients
successfully completed the 3-year follow-up, of
whom 220 patients had received inhaled FP. The
most common reasons for withdrawal were respira-
tory events (n 69, FP group; n 93, placebo
group), the majority being frequent exacerbations as
Table 1—Demographic and Baseline Characteristics*
Characteristics
FP (n  376) Placebo (n  375)
Completed
3 yr
(n  220)
Withdrawn
Prior to 3 yr
(n  156)
Completed
3 yr
(n  182)
Withdrawn
Prior to 3 yr
(n  193)
Age, yr 63.2 (6.8) 64.5 (7.5) 62.8 (7.1) 64.6 (7.0)
Male gender, % 75 76 71 77
Atopy, % 26 29 24 24
Continuous smokers, % 34 40 38 40
Continuous ex-smokers, % 46 47 46 46
Smoking pack-yr 44.4 (28.8) 44.3 (31.2) 42.7 (31.2) 45.0 (36.7)
Tlco, mmol/min/kPa 4.95 (2.08) 4.62 (2.04) 5.28 (2.14) 4.38 (2.03)
Kco, mmol/min/kPa/L 1.02 (0.64) 0.98 (0.66) 1.08 (0.50) 0.90 (0.48)
Previous use of regular inhaled
corticosteroids, %
52 50 †50 †64
Baseline postbronchodilator
FEV1, L
1.42 (0.47) 1.43 (0.48) 1.47 (0.50) 1.34 (0.47)
Baseline % predicted
postbronchodilator FEV1, L
49.8 (14.9) 51.3 (15.1) 52.0 (14.6) 48.2 (15.4)
*Data are presented as mean (SD) unless otherwise indicated. Tlco  diffusing capacity; Kco  diffusion coefficient.
†p  0.01 between identified groups (Fisher exact test).
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defined in the protocol. Thirty-five patients with-
drew due to cardiac events, and 30 patients withdrew
due to the development of a malignancy. Forty-nine
patients either admitted to not taking any study
medication or failed to return for follow-up. The
remaining patients withdrew due to a variety of other
individually infrequent adverse events or for social
reasons. There was no difference in the frequency of
nonrespiratory withdrawals between the two groups
(p 0.5). The time to withdrawal from all causes in
placebo- and FP-treated patients is illustrated by the
Kaplan-Meier plot in Figure 1. Patients withdrew
steadily throughout the study. At all time points,
more patients withdrew while receiving placebo at
each time point. The median number of exacerba-
tions during FP treatment was 0.99/yr irrespective of
subsequent withdrawal. In those receiving placebo, it
was 1.05/yr in those completing but 1.69/yr in those
who did not complete the trial (p 0.02).
Spirometry and Withdrawal
The study population was separated into two
groups on the basis of an FEV1 of  50% predicted
(American Thoracic Society stage 3). In patients with
a higher FEV1, the number of patients completing
and withdrawing during the study were similar in
patients with a higher FEV1 ( 50% predicted), with
46% of the total withdrawing. When the FEV1 was
 50% predicted, there was a clear difference be-
tween the two treatments, with significantly more
patients withdrawing from placebo compared with FP
treatment (57% vs 38%, respectively; p 0.0002). The
reasons for withdrawal were similar in each group as a
percentage of the total causes listed, but the absolute
numbers were lower in the FP-treated patients.
The rate of decline in FEV1 is presented in Fig-
ure 2. The effect of treatment on the rate of decline
in FEV1 was the same in patients who withdrew and
those who completed the study (Table 2, Fig 2);
however, patients who completed the study had a
significantly slower decline in FEV1 than those who
withdrew, irrespective of treatment group (p 0.02).
Health Status and Withdrawal
Baseline health status data for the SGRQ and
SF-36 were similar in all domains at study entry
irrespective of subsequent withdrawal. The rate of
decline of health status in those withdrawing in the
FP group did not differ from that in the placebo
completers (Table 2). In contrast, the deterioration
Figure 1. Kaplan-Meier plots of the number of patients remain-
ing in the study in both FP and placebo groups, and patient
survival allowing for withdrawal from all causes.
Figure 2. Mean rate of change of the postbronchodilator FEV1 over 3 years in patients receiving
placebo who withdrew and completed the study, and those receiving FP who withdrew and completed
the study.
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in SGRQ total, symptoms, and impacts scores of
placebo-treated patients who withdrew was signifi-
cantly greater than that of placebo completers or the
patients treated with FP (p 0.01). The total SGRQ
score of patients withdrawing from placebo deterio-
rated at 6.74 U/yr, equivalent to a clinically notice-
able deterioration in health status every 8 months
(Fig 3). The rate of change in the SF-36 physical
function and health perception scores in placebo-
treated patients who withdrew was greater compared
to the other three groups (p 0.001).
Discussion
This is the first prospective COPD study in which
large numbers of patients failed to complete the
intended follow-up period because of nonrandom
withdrawal. Like other studies6–9 of inhaled cortico-
steroids, our trial did not show a significant effect on
the primary outcome measure, rate of decline of
FEV1; however, patients withdrawing from our study
had a more rapid deterioration in lung function and
health status assessed prior to withdrawal. Loss of
these patients from the trial is likely to have reduced
the power of the investigation to show differences
between groups, and suggests that the effects that
were reported are a conservative estimate of the
impact of treatment.
At randomization, there were no significant differ-
ences between the treatment groups. During the
trial, almost half the patients withdrew, principally
due to their need for repeated courses of oral
Figure 3. Mean rate of change of the SGRQ total score over 3 years in patients receiving placebo who
withdrew and completed the study, and those receiving FP who withdrew and completed the study. An
increase in score represents worsening of health status.
Table 2—Decline in Postbronchodilator FEV1 and Health Status*
Variables
FP
p Value
Placebo
p Value
Completers
(n  211)
Withdrawers
(n  107)
Completers
(n  175)
Withdrawers
(n  123)
Postbronchodilator FEV1 46 mL/yr (n 220) 74 mL/yr (n  119)  0.02 51 mL/yr (n  181) 95 mL/yr (n  144)  0.02
SGRQ total 2.00 2.79 0.4 2.65 6.74 0.0001
SGRQ symptoms 1.15 0.64 0.6 1.99 4.81 0.009
SGRQ activity 2.04 3.86 0.08 3.06 7.02 0.0001
SGRQ impacts 2.21 2.80 0.6 2.63 7.35 0.0001
SF-36 physical function  1.81  2.40 0.6  2.82  7.10 0.0001
SF-36 physical role  3.23  3.64 0.9  4.47  11.06 0.005
SF-36 pain  1.25  3.55 0.2  2.31  2.08 0.8
SF-36 health perception  2.49  2.28 0.9  2.25  7.10 0.0001
SF-36 energy/vitality  1.22  2.43 0.3  2.07  5.59 0.001
SF-36 social function  1.22  2.43 0.3  2.07  5.59 0.001
SF-36 mental role  4.51  6.08 0.6  5.40  7.82 0.4
SF-36 mental health  0.02  0.32 0.8  0.99  2.78 0.06
*Data are presented as U/yr unless otherwise indicated.
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corticosteroids. This withdrawal due to repeated oral
corticosteroid use was more common in placebo-
treated patients, and explains the different dropout
rates in between the groups. Post hoc categorization
of patients into completers and withdrawers suggests
an explanation for the different dropout rates in the
FP- and placebo-treatment groups. Placebo-treated
patients who withdrew had a tendency to have a
lower initial FEV1 than those who completed 3 years
of follow-up, a finding not seen in FP-treated pa-
tients. The effect of the inhaled corticosteroid may
have been to allow these more physiologically im-
paired patients to better cope with exacerbations
better, and avoid treatment with oral corticosteroids.
Although patients who had previously received in-
haled corticosteroids were no different in other
respects at study entry,8 they were more likely to
withdraw if randomized to placebo, which is in
keeping with other data from the prerandomization
phase of this study.20
The severity of COPD assessed spirometrically
also influenced both the number withdrawing and
the number of exacerbations that occurred. Patients
with worse spirometric findings were more likely to
withdraw and have exacerbations, and this influ-
enced the ability of treatment to show an effect.
Thus, the effect of FP treatment on respiratory
withdrawals was most evident in patients with more
severe disease (American Thoracic Society stage 3,
ie,  50% predicted FEV1), where 104 patients
withdrew due to respiratory causes compared with
the 54 patients in the less severely affected groups.
These data explain the lower frequency of exacerba-
tions in other trials of inhaled corticosteroids,6,7
where the baseline FEV1 was higher. Selection of
patients by a specified postbronchodilator FEV1 is
therefore likely to be important when exacerbation
frequency is a study outcome. Moreover, the patient
who withdrew were those in whom the FEV1 was
declining most rapidly, providing objective confirma-
tion of their greater disease severity.
Health status measurements, whether disease spe-
cific or generic, deteriorate in patients with COPD,
and this change is less marked in those treated with
inhaled corticosteroids.21 Our analysis shows that an
important consequence of effective treatment is to
prevent the deterioration in health status in those
who would otherwise withdraw. Thus, the health
status change of patients receiving FP who withdrew
was similar to that in the placebo-treated completers.
Impaired health status is associated with increased
health-care utilization22 and increased numbers of
exacerbations.23 The higher median exacerbation
frequency in those withdrawing while receiving pla-
cebo suggests that exacerbations contribute to their
accelerated decline in health status, and the protec-
tive effect of FP arises from the lower number of
exacerbations observed with this drug.
Differential withdrawal from the study might
modify the study outcome. The loss of those patients
with the most rapid decline in FEV1 will reduce the
overall power of the study to show a difference. The
“healthier survivor” effect seen in the placebo-
treated but not the FP-treated patients may reduce
the difference between groups in the rate of decline
of FEV1. This may be important because, as others,
we used a random effects model to estimate the rate
of decline of FEV1, but this is a conservative ap-
proach to detecting differences between treatments,
especially if there are differential dropout rates
between treatment groups. A theoretical analysis of
the magnitude of this effect is shown in Figure 3.
Differential dropout rates between treatment groups
is a relevant consideration for other potential dis-
ease-modifying agents, in which a reduction of exac-
erbations may also occur and similar problems arise.
Avoiding premature withdrawal is clearly a diffi-
cult problem in any study in which an active therapy
is compared with a placebo treatment. This is espe-
cially so when the treatment is already prescribed by
some physicians, and its removal can precipitate an
exacerbation.20 Patients withdrawn should continue
to be followed up even if their medication is
changed, and future trials should consider less rig-
orous criteria than those used here to determine
when a patient should be discontinued from partic-
ipating in the study.
Reporting the number of patients leaving a clinical
trial provides useful additional information about
treatment effectiveness in bronchial asthma,3,4 and
our data suggests that this is also true for COPD. The
significantly different outcomes in those withdrawing
from active and placebo treatment suggests that an
important clinical effect is occurring. Thus, the
impact of inhaled corticosteroids in COPD may be
rather greater than analyses of individual end points
have so far suggested. These benefits are most
marked in patients with an FEV1  50% predicted,
and as such are in line with recommendations for
treatment suggested in the Global Initiative for
Chronic Obstructive Lung Disease management
strategy.13
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